Adalimumab for the treatment of Crohn's disease

Expert Opinion on Biological Therapy

Volumn 8, Issue 7, 2008, Pages 1011-1019

  Devlin, Shane M ^a   Panaccione, Remo ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Adalimumab; Anti TNF; Biologicals; Crohn's disease; Inflammatory bowel disease; Treatment

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CORTICOSTEROID; CORTICOSTEROID DERIVATIVE; DOUBLE STRANDED DNA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; NARCOTIC AGENT; NATALIZUMAB; ORNIDAZOLE; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ABSCESS; ARTHRALGIA; AUTOIMMUNE DISEASE; CELLULITIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DEMYELINATING DISEASE; DISEASE SEVERITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG LABELING; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; FEVER; FOOD AND DRUG ADMINISTRATION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HISTOPLASMOSIS; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; INTESTINE FISTULA; LISTERIOSIS; LIVER DISEASE; LUPUS LIKE SYNDROME; LYMPHOMA; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MORBIDITY; MUCORMYCOSIS; MULTIPLE SCLEROSIS; MYALGIA; NONHODGKIN LYMPHOMA; PATHOGENESIS; PNEUMONIA; PREVALENCE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; REFRACTORY PERIOD; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SCORING SYSTEM; SEPSIS; SOLID TUMOR; STRUCTURED QUESTIONNAIRE; T CELL LYMPHOMA; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; CROHN DISEASE; DRUG APPROVAL; GASTROINTESTINAL AGENTS; HUMANS; IMMUNE SYSTEM; MICE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE;

EID: 47549096291     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.7.1011     Document Type: Review

References (86)

1. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007;13:254-61
2. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996;39:690-7
3. Rubin GP, Hungin AP, Kelly PJ, Ling J. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther 2000;14:1553-9
4. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77:847-69
5. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66
6. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004;2:379-88
7. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database Syst Rev 2005;CD003715. Published online 24 January 2005, doi:10.1002/14651858.CD003715
8. Wild GE. The role of antibiotics in the management of Crohn's disease. Inflamm Bowel Dis 2004;10:321-3
9. Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002;123:33-40
10. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21
11. Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005;128:856-61
12. Belaiche J, Louis E. Corticosteroid treatment in active Crohn's disease. Acta Gastroenterol Belg 1998;61:153-7
13. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-5
14. Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997;41:209-14
15. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994;331:836-41
16. Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002;97:1748-54
17. Sandborn WJ, Lofberg R, Feagan BG, et al. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroentetol 2005;100:1780-7
18. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995;123:132-42
19. Feagan BG, Rochon J, Fedotak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-7
20. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342:1627-32
21. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9
22. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405
23. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004;99:91-6
24. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005;128:862-9
25. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8
26. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23
27. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
28. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23
29. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-18
30. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38
31. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy wirh certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50
32. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32
33. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy fot Crohn's disease. N Engl J Med 2005;353:1912-25
34. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132:1672-83
35. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-8
36. Aggarwal BB, Kohr WJ, Hass PE, et al. Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem 1985;260:2345-54
37. Smith RA, Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem 1987;262:6951-4
38. Kozuch PL, Hanauer SB. General principles and pharmacology of biologies in inflammatory bowel disease. Gastroenterol Clin North Am 2006;35:757-73
39. Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gur 1997;40:443-8
40. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-9
41. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-81
42. Ghezzi P, Cerami A. Tumor necrosis factor as a pharmacological target. Methods Mol Med 2004;98:1-8
43. Fosatti G, Nesbit AM. Effect of the anti-TNF agents, adalimumab, etanercept, infliximab, and certolizumab pegol on the induction of apoptosis in activated peripheral blood lymphocytes and monocytes. Am J Gastroenterol 2005;100
44. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-57
45. Shen C, Assche GV, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005;21:251-8
46. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33; quiz 591.
47. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-38
48. Humira. (adalimumab) [prescribing information] Abbott Park, IL: Abbott Laboratories; 2005
49. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6
50. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-9
51. Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004;10:333-8
52. Sandborn WJ, Hanauer S, Loftus EV Jr, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004;99:1984-9
53. Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005;100:75-9
54. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514
55. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65
56. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106:287-96
57. Rutgeerts PJ, Melilli LE, Li J, Pollack PF. Adalimumab maintains improvement in Inflammatory Bowel Disease Questionnaire (IBDQ) scores over 1 year following the initial attainment of remission in patients with moderately to severely active Crohn's disease: Results of the CLASSIC II Study. Gastroenterology 2006;130:T1125
58. Loftus EV, Colombel JF, Rutgeerts PJ, et al. Short-term adalimumab therapy improves quality of life in patients who had failed infliximab therapy: Results from the GAIN trial. Gastroenterology 2007;132:T1288
59. Feagan BG, Panaccione R, Sandborn WJ, et al. An evaluation of adalimumab on the risk of hospitalization in patients with Crohn's disease, data from CHARM. Gastroenterology 2007;132:T1312
60. Juillerat P, Pittet V, Felley C, et al. Drug safety in Crohn's disease therapy. Digestion 2007;76(2):161-8
61. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-tetm study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35
62. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85
63. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003;98:1315-24
64. Reddy JG, Loftus EV Jr. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am 2006;35:837-55
65. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31
66. Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001;96:722-9
67. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000;95:3469-77
68. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000;95:3490-7
69. Devlin SM, Hu B, Ippoliti A. Mucormycosis presenting as recurrent gastric perforation in a patient with Crohn's disease on glucocorticoid, 6-mercaptopurine, and infliximab therapy. Dig Dis Sci 2007;52:2078-81
70. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30
71. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001;345:1098-104
72. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003;125:32-9
73. Debandt M, Vittecoq O, Descamps V, et al. Anti-TNF-α-induced systemic lupus syndrome. Clin Rheumatol 2003;22:56-61
74. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85
75. Health Canada Website. Drug Advisory. Available from: http://www.hc-sc.gc.ca/dhp-mps/medeff/ advisories-avis/prof/2006/remicade_3_hpc- cps_e.html [Lasr accessed May 17 2008]
76. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-11
77. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Againsr Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40
78. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9
79. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism: by what mechanisms could tumor necrosis factor α antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001;44:1977-83
80. Colombel JF, Sandborn WJ, Reinisch W, et al. Adalimumab safety in Crohn's disease clinical trials. Gastroenterology 2007;132:T1272
81. Atzeni F, Turiel M, Capsoni F, et al. Autoimmunity and anti-TNF-α agents. Ann NY Acad Sci 2005;1051:559-69
82. Prescribing Information. Humira® (adalimumab). Abbott Laboratories. North Chicago, IL, USA; 2007
83. Summary of Product Characteristics. Humira (adalimumab). Abbott Laboratories Ltd. Berkshire, UK; 2007
84. Bartelds GM, WijBrandts CA, Nurmohamed MT, et al. Clinical Response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6
85. Kaila B, Hilsden R, Panaccione R. Establishing patient preference amongst anti-TNF agents in the treatment of Crohn's disease [abstract]. Can J Gastroenterol 2007;21(Suppl A):A201
86. Schreiber S, Reinisch W, Colombel JF, et al. Early Crohn's disease shows high level of remission to therapy with adalimumab: sub-analysis of CHARM. Digestive Disease Week. Washington, DC, 19-24 May 2007 [abstract]. Gastroenterology 2007;132(4 Suppl 1):A-147